top of page
MVX-ONCO-1 Awarded the 2026 Pfizer Research Prize in Oncology (5 February 2026)
The award recognises a personalised cancer immunotherapy vaccine developed by UNIGE and HUG that originated at MaxiVax (now Release Therapeutics) Release Therapeutics (Release Tx) is pleased to announce that our research collaborators at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have been awarded the 2026 Pfizer Research Prize in Oncology for their work on the personalised cancer vaccine MVX-ONCO-1. [i] Established in 1992, the Pfizer Research Pr
Feb 53 min read
Best Poster Awards 2022: Personalized immunotherapy with encapsulated cell technology
Best Poster Awards 2022 – ESMO conference – Our ECT technology as adjuvant to an au tologous cancer vaccine.
Jan 11, 20221 min read
CTI Swiss Medtech Awards
Our ECT technology as adjuvant to an autologous cancer vaccine.
Jan 11, 20171 min read
bottom of page